Hyperprolactinemia: High Prolactin Levels in Women
Key Takeaways
A high prolactin result does not automatically mean that a prolactinoma is present. Testing is not routine for women with regular cycles and no suggestive symptoms. A moderate elevation should usually be repeated under suitable conditions and checked for macroprolactin. When treatment is needed, cabergoline is generally the first choice.
Key evidence: ESHRE unexplained infertility guideline (2023) Pituitary Society prolactinoma consensus (2023) Systematic review of macroprolactinaemia prevalence (2020)
On this page
- What a high result means
- Causes and testing
- Dr Aksoy’s perspective on borderline results
- The diagnostic workup
- Treatment options
- IVF and prolactin
- Pregnancy and prolactinoma
- Frequently asked questions
Receiving a high prolactin result can be unsettling, especially when it is only slightly above the laboratory range. The number alone does not establish a diagnosis.
The first question is usually not “Which treatment do I need?” It is “Is this result reliable, and does it fit the symptoms?”
What current guidance says about high prolactin
An elevated prolactin level needs clinical evaluation. One result does not prove pituitary disease.
Three points matter at the outset:
- For women with regular cycles and unexplained infertility, ESHRE guidance recommends against routine prolactin screening.
- When medication is needed, cabergoline is the preferred dopamine agonist in the Pituitary Society consensus.
- Macroprolactin accounts for about 19% of elevated results (Che Soh et al., 2020). Identifying it can spare a patient an unnecessary MRI or medication.
Prolactin: role and regulation
Prolactin is made by the anterior pituitary gland and supports milk production after birth. Outside pregnancy and breastfeeding, dopamine normally keeps its release under control.
Temporary rises can follow:
- Venipuncture stress during blood draw (2x to 4x rise).
- Nipple stimulation or recent sexual intercourse.
- Physical exercise, high-protein meals, or sleep disruption.
Hyperprolactinemia vs prolactinoma: not the same thing
- Hyperprolactinemia: A laboratory finding showing serum prolactin above normal reference ranges.
- Prolactinoma: A benign, prolactin-secreting pituitary tumour. A microprolactinoma is smaller than 10 mm. A macroprolactinoma is 10 mm or larger.
- Clinical guide: The Pituitary Society consensus notes that prolactin above 200 ng/mL strongly raises suspicion of a prolactinoma, but it is not diagnostic by itself. Below this level, medicines, thyroid disease, sampling stress and macroprolactin also need to be considered before MRI is decided.
Causes of hyperprolactinemia
Physiological, medication and medical causes
- Physiological: Stress, exercise, pregnancy, breastfeeding, sleep.
- Medications: Antipsychotics (risperidone, haloperidol), prokinetics (metoclopramide), and certain SSRIs.
- Medical Conditions: Primary hypothyroidism (elevated TRH), chronic kidney disease, or liver cirrhosis.
- Macroprolactinemia: Inactive IgG-prolactin complexes detected by PEG precipitation testing.
When should prolactin actually be tested?
Prolactin is not measured routinely in every fertility assessment. Testing becomes useful when cycle changes, symptoms, or the clinical context suggest a prolactin disorder.
The ESHRE 2023 Unexplained Infertility Guideline (Romualdi et al., Hum Reprod) explicitly recommends against routine prolactin testing in women with regular cycles and unexplained infertility.
A UK fertility-clinic cohort (Wojcik, Amer and Jayaprakasan, 2022) included 804 ovulatory women undergoing fertility treatment. Mostly mild elevations were not associated with a difference in ongoing pregnancy or live-birth rates. This was an observational study, so it cannot prove that every mild elevation is harmless.
Dr Aksoy’s approach
In an asymptomatic woman with regular cycles, I do not move to MRI or medication because of one mildly raised result. I first repeat the measurement under suitable conditions and exclude macroprolactin. If monomeric prolactin remains raised and pregnancy, medicines, thyroid disease and renal dysfunction do not explain it, I investigate the pituitary even when there are no symptoms.
I do not delay investigation when there is headache, a visual-field change, galactorrhoea, newly irregular cycles, or a marked and rising prolactin level. Treatment is supported when MRI shows a prolactinoma or when the excess prolactin is demonstrably affecting ovulation or oestrogen levels. Mild, stable true hyperprolactinaemia in a woman who ovulates regularly does not need to be driven to zero automatically before IVF.
A 2025 cross-sectional study also found that hyperprolactinaemia was no more common in women with PCOS than in controls. Most mild elevations in that study were explained by venepuncture stress or macroprolactin.
Prolactin testing is justified in these situations:
- irregular cycles, oligomenorrhoea or amenorrhoea,
- galactorrhoea (milky discharge outside breastfeeding),
- documented anovulation,
- headaches or visual changes suggesting a pituitary adenoma,
- polycystic ovary syndrome workup (prolactin is part of the differential per the 2023 International PCOS Guideline),
- women on antipsychotics or other prolactin-raising medications with hormonal symptoms.
For recurrent pregnancy loss, the 2026 ASRM Practice Committee opinion concludes that high-quality evidence linking prolactin disturbances to recurrent miscarriage is lacking.
It does not recommend routine testing unless symptoms such as galactorrhoea or anovulation are also present.
Symptoms of high prolactin in women
In women
The first signs are often cycle changes, absent ovulation or unexpected milk discharge rather than one dramatic symptom:
- Irregular or absent cycles (oligomenorrhoea, amenorrhoea).
- Anovulation and difficulty conceiving.
- Galactorrhea: spontaneous or expressed milky discharge outside breastfeeding.
- Decreased libido (sex drive), vaginal dryness, mood changes.
In men
- Decreased libido, erectile dysfunction.
- Possible changes in semen parameters (concentration, motility, morphology).
- Rarely, gynecomastia.
Symptoms related to a pituitary tumour
When a macroprolactinoma compresses nearby structures, persistent headaches and visual disturbances can appear. Visual-field narrowing may result from pressure on the optic chiasm.
Other pituitary hormone deficiencies may coexist and should be investigated.
Longer-term consequences
Sustained hyperprolactinaemia can lead to oestrogen or testosterone deficiency, with potential effects on bone health (demineralisation), mood, sleep and sexual function. These concerns belong in follow-up, even when the original problem was found on a blood test.
Mechanism: why prolactin blocks ovulation
Persistently high prolactin can interrupt the hormonal conversation between the brain and the ovaries, making ovulation less regular or stopping it altogether.
The mechanism is now well established. Elevated prolactin inhibits kisspeptin neurons in the arcuate nucleus of the hypothalamus.
These neurons are important regulators of reproduction. They project onto GnRH neurons and govern GnRH pulse frequency.
A landmark study (Brown et al., Endocrinology 2019) showed that selectively deleting the prolactin receptor on arcuate kisspeptin neurons abolishes prolactin’s suppression of LH pulses.
In women with hyperprolactinemia, administering kisspeptin can restore LH pulsatility (Hoskova et al., JCEM 2022).
The cascade is: kisspeptin → GnRH → FSH/LH → estradiol → ovulation.
Any disruption of GnRH pulsatility can impair follicular development and ovulation. Correcting confirmed hyperprolactinaemia often allows ovulation to return, although age and other fertility factors still matter.
Diagnosis: the practical workup
The result is confirmed first. Simple explanations are then checked before a pituitary MRI is considered. This sequence helps avoid medicalising a temporary rise.
1. Confirm the measurement
The Pituitary Society recommends repeating prolactin when the result is less than five times the upper limit of normal. If sampling stress remains a concern, measurement through an indwelling cannula can help clarify the result.
In practice:
- follow the laboratory’s instructions and sit quietly before a mid-morning sample,
- no intense exercise, no nipple stimulation, no heavy meal in the preceding 1–2 hours,
- repeat any modestly elevated value under rested conditions before further workup; if stress remains a concern, a sample taken through an indwelling cannula can help.
2. Rule out the obvious
- TSH to rule out hypothyroidism.
- Urea/creatinine and liver function tests as appropriate.
- β-hCG to rule out pregnancy.
- Full medication review.
- Test for macroprolactin (PEG precipitation) if prolactin is moderately elevated (below 200 ng/mL) or if symptoms and imaging are discordant, as described in the Pituitary Society diagnostic approach.
3. Pituitary MRI
A pituitary MRI is considered when hyperprolactinaemia is confirmed and no pregnancy, medicine, thyroid or renal explanation is found after macroprolactin has been assessed. The imaging protocol is selected by the clinical and radiology teams.
4. The hook effect: a pitfall to know
For very large adenomas, some assays can underestimate prolactin. This is an assay saturation effect known as the “hook effect.”
When a very large adenoma is seen but prolactin is only normal or mildly raised, the laboratory can repeat the assay after dilution to exclude this problem.
5. Visual field testing
Indicated when imaging shows the adenoma touches or compresses the optic chiasm. During pregnancy, visual fields are checked each trimester for macroadenomas; only on symptoms for microadenomas.
Treatment: cabergoline first-line
When medication is indicated, cabergoline is generally the preferred first treatment. The cause, symptoms, and any pituitary finding still guide the plan.
Cabergoline
Cabergoline is the dopamine agonist recommended as first-line therapy by the Pituitary Society 2023 and the Endocrine Society. It mimics dopamine’s inhibitory action on prolactin.
- The dose is determined and adjusted by your doctor based on prolactin level, the presence and size of any prolactinoma, and individual tolerance. Treatment usually begins at a low dose, taken once or twice a week, and is gradually titrated.
- Tolerability is usually good; nausea, headache and postural dizziness are often transient. Persistent mood changes or unusual impulsive behaviours are less common but should also be reported.
- Ovulation often returns once prolactin is normalised. Pregnancy chances then depend on age and other fertility factors as well as prolactin.
The pivotal trial (Webster et al., NEJM 1994) found that cabergoline normalised prolactin in 83% of patients, compared with 59% with bromocriptine.
These trial figures describe a selected study population and should not be used to predict an individual’s chance of pregnancy.
Bromocriptine
Bromocriptine remains an option. It may suit patients who already tolerate it well or who need it in a particular pregnancy context.
It has a large historical safety database, with more than 6,000 documented pregnancies. Its tolerability was worse than cabergoline in the 1994 NEJM trial: 78% reported adverse events and 12% stopped treatment because of intolerance.
Quinagolide
Quinagolide is a non-ergot alternative useful in patients intolerant to cabergoline. It is not available in all countries.
Treating the underlying cause
- Hypothyroidism: thyroid hormone replacement can normalise prolactin on its own.
- Causative medication: the prescribing team evaluates adjustment or substitution, never abrupt discontinuation without specialist input.
- Chronic kidney disease or other chronic illness: management of the primary disease shapes the trajectory.
Cardiac surveillance: should you be concerned?
Ergot-derived dopamine agonists have been associated with cardiac valvulopathy at high doses, notably in Parkinson’s disease.
The doses used in hyperprolactinemia are much lower. Available data are reassuring:
- a meta-analysis (Stiles et al., JCEM 2018) found an increased prevalence of subclinical tricuspid regurgitation (OR 3.74; 95% CI 1.79–7.8), without clinically significant valvulopathy;
- a large primary-care cohort study (Stiles et al., JCEM 2021) found no excess heart failure or valve repair.
The Pituitary Society 2023 recommends a baseline echocardiogram when long-term treatment above 2 mg of cabergoline per week is planned, followed by repeat imaging every 2–3 years at that dose. At 2 mg per week or less, echocardiography is suggested after 5–6 years; a new cardiac murmur warrants earlier assessment.
Surgery and radiotherapy
Transsphenoidal surgery is reserved for selected situations:
- resistance or intolerance to dopamine agonists,
- cystic adenomas (often poor response to medical therapy),
- persistent optic chiasm compression,
- cerebrospinal fluid leak,
- macroprolactinoma in a woman planning multiple pregnancies: the Pituitary Society consensus notes that pre-conceptional debulking surgery reduces the risk of symptomatic tumour enlargement in pregnancy from 21% to 4.7%.
A systematic review of 25 surgical studies (Zamanipoor Najafabadi et al., JCEM 2020) found that remission varied substantially with tumour size, extension and surgical expertise. Published averages should therefore be discussed in the context of the individual tumour and centre.
Radiotherapy is much rarer, reserved for aggressive or persistent tumours that do not respond to other approaches.
Resistance to medical therapy
Dopamine agonist resistance means that prolactin does not normalise or the tumour does not shrink by at least 50% at the maximum tolerated dose.
It remains uncommon, particularly with cabergoline (Maiter, Neuroendocrinology 2019). A specialist team may adjust the dose, change medication or discuss surgery; other treatments are reserved for rare, complex cases.
Hyperprolactinemia and IVF
A mild, symptom-free elevation does not automatically need treatment before IVF. A confirmed prolactin disorder that affects ovulation or reflects a prolactinoma is a different situation.
Should mild hyperprolactinemia be treated before IVF?
The available evidence, mainly from retrospective studies, does not support routine treatment of mild asymptomatic hyperprolactinaemia before IVF. Some series found no association with fertilisation, implantation or live birth, but their size and design limit certainty.
Transient elevations during ovarian stimulation
Increasing oestrogen during ovarian stimulation can cause a temporary rise in prolactin. The Iancu et al. 2023 review describes heterogeneous and limited evidence. A temporary stimulation-related rise does not, by itself, justify starting a dopamine agonist.
Continuing treatment during stimulation
For a patient already receiving treatment, the plan depends on the adenoma and the pregnancy strategy. Cabergoline may be continued during stimulation and should be reassessed as soon as pregnancy is confirmed by the team managing the hyperprolactinaemia.
Cabergoline for OHSS prevention
This is a distinct indication. In patients at risk of ovarian hyperstimulation syndrome (OHSS), a short course of a dopamine agonist probably reduces moderate-to-severe OHSS. Effects on live birth, clinical pregnancy and miscarriage remain uncertain in the 2021 Cochrane review. Timing and duration depend on the IVF protocol.
Hyperprolactinemia, prolactinoma and pregnancy
Most microprolactinomas remain stable during pregnancy. Larger or invasive adenomas need an individual monitoring and treatment plan.
Tumor-growth risk during pregnancy
Pregnancy oestrogens can stimulate prolactinoma growth. The following risk estimates come from the Pituitary Society consensus and depend on tumour type:
- Microprolactinoma: about 3% symptomatic growth.
- Untreated macroprolactinoma: 21–32%.
- Macroprolactinoma after surgery or radiotherapy: about 4.8%.
Pituitary Society 2023 recommendations
- Microprolactinoma and non-invasive intrasellar macroprolactinoma: dopamine agonist is stopped at confirmation of pregnancy.
- Invasive macroprolactinoma or chiasmal proximity: continuing treatment through pregnancy may be considered; pre-conceptional debulking surgery is an alternative.
- Visual field testing: each trimester for macroadenomas, only on symptoms for microadenomas.
- MRI without gadolinium: performed if new headaches or visual changes develop.
- Prolactin measurement is not informative during pregnancy (physiological elevation).
- Reintroduction of dopamine agonist to be considered for clinically significant adenoma growth.
Cabergoline safety in early pregnancy
More than 1,300 cabergoline-exposed pregnancies have been described in historical series, including Lebbe et al. (2010).
The 2025 Chakraborty meta-analysis included 1,387 pregnancies (PMID 40629810). It found no significant increase in major malformations with first-trimester exposure. The 2025 Otis systematic review reached a similar conclusion, but the studies were heterogeneous and generally of low quality.
In the meta-analysis, continuation beyond six weeks was associated with a lower live-birth rate. This observational association does not establish that cabergoline caused the difference. Treatment should therefore not continue automatically after pregnancy is confirmed; the decision depends on adenoma size and clinical risk.
Bromocriptine retains the largest historical pregnancy database (more than 6,000 documented pregnancies) — an acceptable alternative, particularly when already well tolerated before pregnancy.
Breastfeeding
Breastfeeding is not contraindicated for a stable microprolactinoma or non-progressive macroprolactinoma. Dopamine agonists suppress lactation and are usually withheld during breastfeeding, except in case of tumour growth.
Before conception
Before conception, the aim is a stable prolactin level and the return of regular cycles. This helps with pregnancy dating and allows the treatment plan for a positive test to be agreed in advance.
Quality of life and support
The impact is not limited to a laboratory value. Cycle changes, galactorrhoea, erectile difficulties, fatigue and changes in sexual wellbeing can affect confidence, relationships and the emotional experience of fertility treatment. These concerns deserve space in the consultation; psychological support can also help during a long fertility or IVF journey.
In practice
A high prolactin result is a signal to understand, not a diagnosis by itself. The most useful next step is often confirmation and a search for the cause rather than immediate treatment.
The practical points are:
- do not test prolactin routinely in every fertility assessment — test when symptoms or clinical signs suggest it,
- check for macroprolactin when prolactin is moderately elevated and symptoms are absent or discordant,
- cabergoline as first-line when medical treatment is indicated,
- stop treatment at confirmation of pregnancy for microadenomas and most non-invasive macroadenomas, with appropriate surveillance,
- do not treat stimulation-related transient prolactin rises or mild asymptomatic hyperprolactinemia before IVF.
Most cases respond well once the cause is identified. Fertility can return when prolactin is normalised.
Other infertility factors may still affect the outcome.
FAQ
Should prolactin be tested in every fertility assessment?
No. The ESHRE unexplained infertility guideline recommends against routine prolactin testing in women with regular cycles and unexplained infertility. Testing is indicated in case of cycle disturbances, galactorrhoea, anovulation, pituitary symptoms or polycystic ovary syndrome.
Is a moderately elevated prolactin always pathological?
Not necessarily. Stress, the blood draw itself, short sleep, a protein-rich meal, certain medications, or macroprolactin can all explain a moderate elevation. A repeat measurement under better conditions, sometimes with macroprolactin testing, is often the first step.
What is macroprolactin and why does it matter?
Macroprolactin is a complex between prolactin and an immunoglobulin. Standard assays can detect it, but it has little biological effect.
It accounts for about 19% of hyperprolactinaemic cases in a systematic review and meta-analysis. PEG precipitation testing can prevent unnecessary medication and pituitary MRI.
When is a pituitary MRI ordered?
According to the Pituitary Society diagnostic approach, MRI is considered when prolactin remains elevated after pregnancy, medicines, thyroid or renal disease and macroprolactin have been assessed. Headaches, visual changes or prolonged amenorrhoea can make imaging more urgent. If a very large tumour is accompanied by an unexpectedly low prolactin result, the laboratory can repeat the assay after dilution to check for the “hook effect.”
Cabergoline or bromocriptine: which to choose?
Cabergoline is first-line in the Pituitary Society consensus. In the Webster et al. comparative trial, it normalised prolactin in 83% of participants, compared with 59% for bromocriptine, and was generally better tolerated.
Bromocriptine retains specific indications. These include good previous tolerability and its larger historical pregnancy safety database.
Can you get pregnant on cabergoline?
Yes — that is often the goal. Once prolactin is normalised and ovulation returns, conception becomes possible.
Cabergoline is usually stopped when pregnancy is confirmed in microadenomas and non-invasive intrasellar macroadenomas. A 2025 meta-analysis found no clear increase in major malformations, although the evidence is observational and heterogeneous.
Should mild hyperprolactinemia be treated before IVF?
For a mild, stable elevation without cycle disturbance or galactorrhoea, the available evidence has not shown that routine treatment improves IVF outcomes. The Iancu et al. review describes the evidence as limited and heterogeneous; a temporary rise during stimulation, on its own, is not a reason to start a dopamine agonist.
Sources
- Petersenn S, Fleseriu M, Casanueva FF, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol 2023;19(12):722–740.
- Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2011;96(2):273–288.
- Romualdi D, Ata B, Bhattacharya S, et al. (ESHRE Guideline Group). Evidence-based guideline: unexplained infertility. Hum Reprod 2023;38(10):1881–1890.
- Teede HJ, Tay CT, Laven JSE, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2023;108(10):2447–2469.
- Luque-Ramírez M, Quintero-Tobar A, Martínez-García MÁ, et al. Mild hyperprolactinemia in women with polycystic ovary syndrome: insights from a large cross-sectional study. J Clin Transl Endocrinol 2025;41:100412.
- Che Soh NAA, Yaacob NM, Omar J, et al. Global prevalence of macroprolactinemia among patients with hyperprolactinemia: a systematic review and meta-analysis. Int J Environ Res Public Health 2020;17(21):8199.
- Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994;331:904–909.
- Stiles CE, Tetteh-Wayoe ET, Bestwick JP, et al. Meta-analysis of the prevalence of cardiac valvulopathy in patients with hyperprolactinemia treated with cabergoline. J Clin Endocrinol Metab 2018;104(2):523–538.
- Brown RSE, Herbison AE, Grattan DR. Acute suppression of LH secretion by prolactin in female mice is mediated by kisspeptin neurons in the arcuate nucleus. Endocrinology 2019;160:1323–1332.
- Hoskova K, Bryant NK, Chen ME, et al. Kisspeptin overcomes GnRH neuronal suppression secondary to hyperprolactinemia in humans. J Clin Endocrinol Metab 2022;107(8):e3515–e3525.
- Stiles CE, Lloyd G, Bhattacharyya S, et al. Incidence of cabergoline-associated valvulopathy in primary care patients with prolactinoma using hard cardiac endpoints. J Clin Endocrinol Metab 2021;106(2):e711–e720.
- Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F, et al. Surgery as a viable alternative first-line treatment for prolactinoma patients: a systematic review and meta-analysis. J Clin Endocrinol Metab 2020;105(3):e32–e41.
- American Society for Reproductive Medicine Practice Committee. Recurrent pregnancy loss: a committee opinion. Fertil Steril 2026.
- Tang H, Mourad SM, Wang A, Zhai S-D, Hart RJ. Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2021;4:CD008605. doi:10.1002/14651858.CD008605.pub4.
- Lebbe M, Hubinont C, Bernard P, Maiter D. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clin Endocrinol 2010;73(2):236–242.
- Otis AS, et al. Cabergoline use and pregnancy outcomes: a systematic review. Birth Defects Res 2025;117(3):e2464.
- Chakraborty AM, Rastogi A. Safety of Cabergoline for Prolactinoma in Pregnancy: A Systematic Review and Meta-Analysis. Clin Endocrinol (Oxf) 2025;103(5):633–640. doi:10.1111/cen.15304.
- Wojcik M, Amer S, Jayaprakasan K. The prevalence of hyperprolactinaemia in subfertile ovulatory women and its impact on fertility treatment outcome. J Obstet Gynaecol 2022;42(6):2349–2353. doi:10.1080/01443615.2022.2049727.
- Maiter D. Management of Dopamine Agonist-Resistant Prolactinoma. Neuroendocrinology 2019;109(1):42–50.
- Iancu ME, Albu AI, Albu DN. Prolactin Relationship with Fertility and In Vitro Fertilization Outcomes—A Review of the Literature. Pharmaceuticals 2023;16(1):122. doi:10.3390/ph16010122.
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.